These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 30993835)

  • 1. All-cause pneumonia in children after the introduction of pneumococcal vaccines in the United Kingdom: A population-based study.
    Lau WCY; Bielicki J; Tersigni C; Saxena S; Wong ICK; Sharland M; Hsia Y
    Pharmacoepidemiol Drug Saf; 2019 Jun; 28(6):821-829. PubMed ID: 30993835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of pneumococcal conjugate vaccines on childhood otitis media in the United Kingdom.
    Lau WC; Murray M; El-Turki A; Saxena S; Ladhani S; Long P; Sharland M; Wong IC; Hsia Y
    Vaccine; 2015 Sep; 33(39):5072-9. PubMed ID: 26297875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term Impact of Pneumococcal Conjugate Vaccines on Invasive Disease and Pneumonia Hospitalizations in Indigenous and Non-Indigenous Australians.
    Meder KN; Jayasinghe S; Beard F; Dey A; Kirk M; Cook H; Strachan J; Sintchenko V; Smith H; Giele C; Howden B; Krause V; Mcintyre P
    Clin Infect Dis; 2020 Jun; 70(12):2607-2615. PubMed ID: 31388670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. All-cause pneumonia hospitalizations in children <2 years old in sweden, 1998 to 2012: impact of pneumococcal conjugate vaccine introduction.
    Berglund A; Ekelund M; Fletcher MA; Nyman L
    PLoS One; 2014; 9(11):e112211. PubMed ID: 25379659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Additive impact of pneumococcal conjugate vaccines on pneumonia and empyema hospital admissions in England.
    Saxena S; Atchison C; Cecil E; Sharland M; Koshy E; Bottle A
    J Infect; 2015 Oct; 71(4):428-36. PubMed ID: 26159503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001-2012.
    Lepoutre A; Varon E; Georges S; Dorléans F; Janoir C; Gutmann L; Lévy-Bruhl D; ;
    Vaccine; 2015 Jan; 33(2):359-66. PubMed ID: 25448105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence of acute otitis media from 2003 to 2019 in children ≤ 17 years in England.
    Mohanty S; Podmore B; Cuñado Moral A; Weiss T; Matthews I; Sarpong E; Méndez I; Qizilbash N
    BMC Public Health; 2023 Jan; 23(1):201. PubMed ID: 36717794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Invasive pneumococcal disease incidence in children and adults in France during the pneumococcal conjugate vaccine era: an interrupted time-series analysis of data from a 17-year national prospective surveillance study.
    Ouldali N; Varon E; Levy C; Angoulvant F; Georges S; Ploy MC; Kempf M; Cremniter J; Cohen R; Bruhl DL; Danis K
    Lancet Infect Dis; 2021 Jan; 21(1):137-147. PubMed ID: 32702302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative incidence dynamics and serotypes of meningitis, bacteremic pneumonia and other-IPD in young children in the PCV era: Insights from Israeli surveillance studies.
    Ben-Shimol S; Givon-Lavi N; Grisaru-Soen G; Megged O; Greenberg D; Dagan R;
    Vaccine; 2018 Aug; 36(36):5477-5484. PubMed ID: 28579230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of PCV7/PCV13 introduction on community-acquired alveolar pneumonia in children <5 years.
    Greenberg D; Givon-Lavi N; Ben-Shimol S; Ziv JB; Dagan R
    Vaccine; 2015 Aug; 33(36):4623-9. PubMed ID: 26116251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in empyema among U.S. children in the pneumococcal conjugate vaccine era.
    Wiese AD; Griffin MR; Zhu Y; Mitchel EF; Grijalva CG
    Vaccine; 2016 Dec; 34(50):6243-6249. PubMed ID: 27832918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence of acute otitis media in children in the United States before and after the introduction of 7- and 13-valent pneumococcal conjugate vaccines during 1998-2018.
    Hu T; Done N; Petigara T; Mohanty S; Song Y; Liu Q; Lemus-Wirtz E; Signorovitch J; Sarpong E; Weiss T
    BMC Infect Dis; 2022 Mar; 22(1):294. PubMed ID: 35346092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.
    Jayasinghe S; Menzies R; Chiu C; Toms C; Blyth CC; Krause V; McIntyre P
    Clin Infect Dis; 2017 Jan; 64(2):175-183. PubMed ID: 27986682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Declines in pneumonia hospitalizations of children aged <2 years associated with the use of pneumococcal conjugate vaccines - Tennessee, 1998-2012.
    Griffin MR; Mitchel E; Moore MR; Whitney CG; Grijalva CG;
    MMWR Morb Mortal Wkly Rep; 2014 Nov; 63(44):995-8. PubMed ID: 25375070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early impact of sequential introduction of 7-valent and 13-valent pneumococcal conjugate vaccine on IPD in Israeli children <5 years: an active prospective nationwide surveillance.
    Ben-Shimol S; Greenberg D; Givon-Lavi N; Schlesinger Y; Somekh E; Aviner S; Miron D; Dagan R
    Vaccine; 2014 Jun; 32(27):3452-9. PubMed ID: 24690148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Childhood Pneumococcal Conjugate Vaccine on Nonnotified Clinically Suspected Invasive Pneumococcal Disease in Australia.
    Gidding HF; Sheridan S; Fathima P; Moore HC; Liu B; McIntyre PB; Palmu AA;
    Pediatr Infect Dis J; 2019 Aug; 38(8):860-865. PubMed ID: 30985507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study.
    Waight PA; Andrews NJ; Ladhani SN; Sheppard CL; Slack MP; Miller E
    Lancet Infect Dis; 2015 May; 15(5):535-43. PubMed ID: 25801458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pneumonia hospitalization after introduction of pneumococcal conjugate vaccine in Japan: Descriptive study using a nationwide claims database.
    Yanai T; Yoshida S; Takeuchi M; Kawakami K
    Vaccine; 2023 Jun; 41(29):4313-4318. PubMed ID: 37286407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dynamics of Severe and Non-severe Invasive Pneumococcal Disease in Young Children in Israel Following PCV7/PCV13 Introduction.
    Glikman D; Dagan R; Barkai G; Averbuch D; Guri A; Givon-Lavi N; Ben-Shimol S;
    Pediatr Infect Dis J; 2018 Oct; 37(10):1048-1053. PubMed ID: 29750768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of the 13-valent pneumococcal conjugate vaccine on the incidences of community-acquired pneumonia and pneumonia-related hospitalizations in children ≤5 years after its implementation into the national immunization program of Turkey.
    Gönüllü E; Soysal A; Yıldız I; Aydemir G; Tunç T; Karaböcüoğlu M
    Hum Vaccin Immunother; 2020 Oct; 16(10):2504-2508. PubMed ID: 32119602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.